Xeme Biopharma Incis Clinical Stage Company Focused On Developing Therapeutic Products In The Area Of Active Cancer Immunotherapyvaccines This Area Of Therapeutic Cancer Vaccines Is Expected By Many Oncology Specialists To Provide The Next Breakthrough In The Treatment Of Cancer Beyond The Current Approaches Of Surgeryradiationchemotherapy And Passive Immunotherapymonoclonal Antibodiesxeme Biopharma Is Focused On Two Integrated Technology Platformsaggregonaand Oncolipinthe Aggregonatechnology Is Used In The Manufacture Of Oncoquesta C Cll And Oncoquesta C Ltwo Innovative Lead Products Of Personalizedautologouscancer Vaccines For The Treatment Of Leukemia And Lymphomarespectively Xeme S Uniquedisruptiveand Patented Technology Platform Has The Following Competitive Advantages Indicated Efficacy In Previous Clinical Studiesvery Low Cost Of Production High Marginsbroad Spectrum Of Potential Clinical Applications Personalized And Off The Shelf Productsrapid Manufacturing Processless Than 24 Hoursrelatively Low Cost Per Doseper Patient
